GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...

Philogen immunocytokine for brain cancerUniversity of Zurich and Swiss Federal Institute of Technology Zurich (ETHZ) scientists reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of Philogen S.p.A.’s Fibromun (L19-TNF)...

Via a deal with Gilead yielding $120 million in upfront cash for rights to a preclinical oncology program, Jounce will extend its cash runway into 2023 as it presses forward with a lead program on...

COVID-19 diagnostic developments this week include the addition of two types of COVID-19 rapid test kits by Celltrion and Verily’s move to boost capacity with a new CLIA lab in South San Francisco. ...

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...

U.K. clears early access to lumasiran The U.K.’s Medicines and Healthcare products Regulatory Agency is making lumasiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) available to patients with primary hyperoxaluria type I before its approval by the...

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...

A consortium that is pooling the resources of the U.S. government and global biopharmaceutical companies to discover and develop drugs and vaccines for COVID-19 has selected a first wave of therapies for testing and plans...

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...